Pricing Log in Create free account
Saturday 7 November 2026 Export SER’s income statement to Excel — free account

Serina Therapeutics, Inc.

SER Healthcare Biotechnology

Serina Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $130,000.00, up 132.1% from fiscal 2024.

Revenue
+2,500.0%
EPS
+16.7%
Free cash flow
−76.8%

Quarter to June 2026, against a year earlier

1.40 0.25 −15.15%
Market cap
$41.9M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
2/9
Altman Z
−22.07
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.08
Sold, $m 0.31
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — 3 1 1 — — — —
Sell 7 5 1 2 — — — — — — — —
Insider Ownership 24.32%

Capital & Financial Ratios $m

Size
Market Cap 41.91
Revenue ttm 0.18
Net income ttm (21.18)
Free cash flow ttm (21.20)
Net debt Q (19.94)
Valuation
P/E 0.00
Forward P/E (1.23) (negative: loss-making)
Price / sales 126.73 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.22
Financial health
Current ratio Q 6.65 (at or above 1.5: strong)
Debt / equity Q 0.16 (at or below 0.5: strong)
Interest coverage Q (33.42)
Growth
Revenue growth Q +2,500.00% (above 0%: growing)
Operating income growth Q −21.90% (below 0%: shrinking)
EPS, this year +17.35% (at or above 15%: strong)
EPS, next year A +26.95% (at or above 15%: strong)
Revenue, next year A 0.00%
EPS, past 5 yrs —
EPS, next 5 yrs A +18.02% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 32.5×, against a ten-year median of 150×; over the ten years it ranged from 6.6× in 2024 to 1,870× in 2023.
P/S against its own 10 years 46.08%
10-year low 10-year high
EV/Sales against its own 10 years 21.94%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 8 4 3 23
Receivables — — — —
Inventory — — — —
Other — — — —
8 6 6 25
2023 2024 2025 Q'26
Payables 1 1 2 2
ST’ Debt — — — —
Other 0 0 0 1
1 2 4 4

Compound Annual Growth %

10y 5y 3y
Sales — (18.48%) 56.37%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY25 Estimate −0.47 Actual −0.45

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY25 −0.36 −0.66 Miss by 0.30
Q3 FY25 −0.47 −0.45 Beat by 0.02

EPS $

Mar Jun Sep Dec Year
’26 (0.58) (0.55) — — —
’25 (0.49) (0.66) (0.45) (0.31) (1.91)
’24 (5.38) 0.51 0.13 (0.48) (1.51)
’23 0.19 0.11 0.23 0.18 0.72
’22 (2.46) (2.46) (2.11) (2.46) (9.86)
’21 (2.11) (2.46) (1.76) (2.00) (8.10)
’20 (2.82) (2.46) (2.46) (2.46) (10.21)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — 0 — — 0
’24 0 0 0 0 0
’23 0 0 0 3 3
’22 0 0 0 0 0
’21 0 0 0 0 0
’20 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (7) — — —
’25 (4) (4) (4) (6) (18)
’24 (2) (8) (3) (5) (17)
’23 (1) (1) (1) 0 (2)
’22 (2) (2) (1) (1) (6)
’21 (3) (2) (2) (2) (8)
’20 (2) (2) (2) (2) (8)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (7) — — —
’25 (4) (4) (4) (6) (18)
’24 (2) (8) (3) (5) (17)
’23 (1) (1) (1) 0 (3)
’22 (2) (2) (1) (1) (6)
’21 (3) (2) (2) (2) (8)
’20 (2) (2) (2) (2) (8)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 2 1 1 2 0 0 0 3 0 0 0 (24.7%) 0 0 — 0.0%
Gross margin, % 45.32 88.03 73.93 85.88 92.80 86.81 61.76 100.00 100.00 100.00 100.00 +54.7 pt
EBT (17) (7) (8) (12) (11) (9) (11) 5 (11) (19) (21) +1.1%
EBT margin, % (1,041.72) (472.72) (553.80) (708.10) (3,081.99) (5,959.72) (30,947.06) 167.11 (20,012.50) (14,766.92) 0.00 (13,725.2) pt
Net income (15) (7) (8) (12) (10) (9) (10) 5 (11) (19) (21) +2.4%
Per share, $
Per share, $ Revenue 0.05 1.61 1.41 1.63 0.34 0.13 0.03 1.41 0.01 0.01 0.00 (13.4%)
Earnings (0.43) (7.63) (7.39) (11.62) (10.21) (8.10) (9.86) 2.36 (1.51) (1.91) (1.89) +18.0%
Cash flow (0.24) (7.22) (8.06) (9.60) (7.31) (7.30) (5.50) (1.11) (2.33) (1.76) (1.29) +25.1%
Capex 0.00 0.00 (0.02) (0.61) (0.02) 0.00 0.00 (0.23) 0.00 (0.01) 0.00 n/m
Free cash flow (0.24) (7.22) (8.08) (10.20) (7.33) (7.30) (5.50) (1.33) (2.33) (1.77) (1.29) +25.1%
Book value (0.65) 9.56 8.30 2.47 (5.04) (11.04) (16.05) (14.45) 0.07 0.00 1.14 (43.9%)
Shares, m 36 1 1 1 1 1 1 2 7 10 12 (13.0%)
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.25 0.00 0.00 0.00 0.6
P/S 0.00 0.00 76.66 39.22 158.43 286.49 623.92 10.44 658.37 107.53 126.73 196.1
P/B 11.65 11.65 13.00 25.89 0.00 0.00 0.00 0.00 72.58 0.00 1.22 13.5
EV/Sales 0.00 0.00 71.86 38.99 174.41 374.11 1,138.00 9.46 673.33 122.88 32.54 260.3
EV/FCF 0.00 (7.30) (12.51) (6.24) (8.03) (6.84) (6.49) (10.00) (2.20) (1.23) (0.28) (6.1)
Cash, $m
Cash, $m Operating cash flow (8) (6) (8) (10) (8) (8) (6) (2) (17) (18) (21) +8.8%
Capex 0 0 0 (1) 0 — — (1) 0 0 0 +11.0%
Free cash flow (8) (6) (8) (11) (8) (8) (6) (3) (17) (18) (21) +8.8%
Balance, $m
Balance, $m Working capital (25) 6 5 1 (3) (7) (8) 6 3 3 21 n/m
Net debt 0 (7) (7) (1) 3 5 10 (5) (4) 0 (20) (9.1%)
Shareholders’ equity (23) 8 8 3 (5) (12) (17) (32) 1 0 19 (51.2%)
Returns, %
Returns, % ROA (241.05) (102.38) (73.90) (134.20) (191.17) (245.09) (327.19) 86.31 (142.00) (280.54) (136.00) (39.5) pt
ROIC 0.00 (441.14) (461.16) (437.78) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE 191.98 87.15 (90.66) (224.08) 781.94 100.46 71.68 (21.24) 70.10 858.45 (306.22) +666.5 pt
People
People Employees — 17 12 17 11 10 9 8 13 16 — (0.8%)
Revenue/emp, $m 0.00 0.08 0.12 0.10 0.03 0.01 0.00 0.39 0.00 0.01 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2025 · fundamentals updated 25 Oct 2026

Serina Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BMEA Biomea Fusion, Inc. $42.6M — (loss-making) — — n/m +47.80% (above 0%: growing) 0.00% 0.00% Compare
ATHE Alterity Therapeutics Limited - Sponsored ADR $42.4M — (loss-making) — — 0.00% −84.83% (below 0%: shrinking) 0.00% — Compare
SER Serina Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) +2,500.00% (above 0%: growing) n/m −76.82% (below 0%: shrinking) 100.00% 0.00%
GANX Gain Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) +27.78% (above 0%: growing) n/m +8.22% (above 0%: growing) 0.00% 0.00% Compare
SGMOQ Sangamo Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) −77.60% (below 0%: shrinking) n/m +26.21% (above 0%: growing) 100.00% (2,215.40%) Compare
LONA LeonaBio, Inc. $40.9M — (loss-making) — — n/m −142.29% (below 0%: shrinking) 0.00% 0.00% Compare
ATNM Actinium Pharmaceuticals, Inc. $40.9M 3.9× 8.4× +77,677.78% (above 0%: growing) n/m −4.91% (below 0%: shrinking) 100.00% 78.76% Compare
HYPD Hyperion DeFi, Inc. $39.8M — (loss-making) 0.5× +2,333.33% (above 0%: growing) n/m +86.82% (above 0%: growing) 100.00% 8,668.63% Compare
DWTX Dogwood Therapeutics, Inc $39.8M — (loss-making) — — n/m +10.31% (above 0%: growing) — 0.00% Compare
Median of peers $41.4M — — +1,180.56% — +9.27% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 27 April 2026

Ownership

Directors and executive officers, together 43.40% of the votes
Gregory H. Bailey, M.D. 37.90% of the votes
Juvenescence Limited and certain affiliates 16.50% of the votes
Puffinus L.P. 7.00% of the votes
Jay Venkatesan, M.D. 1.00% of the votes
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Serina Therapeutics, Inc. (SER) Latest News

9 Sep

Impact 4 ·
Impact 4 · · GlobeNewswire

13 Aug

Impact 3 ·

23 Jul

Impact 3 ·

9 Jul

Impact 3 ·

30 Jun

Impact 3 ·

14 May

Impact 3 · · GlobeNewswire
Impact 3 ·

2 Apr

Impact 4 · · GlobeNewswire

25 Mar

Impact 3 · · GlobeNewswire

18 Mar

Impact 4 · · GlobeNewswire

24 Feb

Impact 4 · · GlobeNewswire

19 Feb

Impact 4 · · GlobeNewswire

3 Feb

Impact 3 · · GlobeNewswire

28 Jan

Impact 4 · · GlobeNewswire

15 Jan

Impact 3 · · GlobeNewswire

11 Dec

Impact 3 · · GlobeNewswire

10 Dec

Impact 4 · · GlobeNewswire

13 Nov

Impact 3 · · GlobeNewswire

3 Nov

Impact 4 · · GlobeNewswire

8 Oct

Impact 3 · · GlobeNewswire

6 Oct

Impact 4 · · GlobeNewswire

25 Aug

Impact 4 · · GlobeNewswire

11 Aug

Impact 3 ·

29 Jul

Impact 4 · · GlobeNewswire

28 Jul

Impact 3 · · GlobeNewswire

23 Jun

Impact 4 · · GlobeNewswire

17 Jun

Impact 4 · · GlobeNewswire
Impact 3 ·

22 May

Impact 3 ·
stockrow.com/SER · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com